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ABSTRACT
Etoposide and other topoisomerase II-targeted drugs
are important anticancer therapeutics. Unfortunately,
the safe usage of these agents is limited by their in-
discriminate induction of topoisomerase II-mediated
DNA cleavage throughout the genome and by a
lack of specificity toward cancer cells. Therefore, as
a first step toward constraining the distribution of
etoposide-induced DNA cleavage sites and develop-
ing sequence-specific topoisomerase II-targeted an-
ticancer agents, we covalently coupled the core of
etoposide to oligonucleotides centered on a topoi-
somerase II cleavage site in the PML gene. The initial
sequence used for this ‘oligonucleotide-linked topoi-
somerase inhibitor’ (OTI) was identified as part of
the translocation breakpoint of a patient with acute
promyelocytic leukemia (APL). Subsequent OTI se-
quences were derived from the observed APL break-
point between PML and RARA. Results indicate that
OTIs can be used to direct the sites of etoposide-
induced DNA cleavage mediated by topoisomerase
II and topoisomerase II. OTIs increased levels of
enzyme-mediated cleavage by inhibiting DNA liga-
tion, and cleavage complexes induced by OTIs were
as stable as those induced by free etoposide. Finally,
OTIs directed against the PML-RARA breakpoint
displayed cleavage specificity for oligonucleotides
with the translocation sequence over those with se-
quences matching either parental gene. These stud-
ies demonstrate the feasibility of using oligonu-
cleotides to direct topoisomerase II-mediated DNA
cleavage to specific sites in the genome.
INTRODUCTION
Type II topoisomerases are ubiquitous enzymes that regu-
late DNA topology by creating transient double-stranded
breaks in the DNA (1–6). As a result of their activity, they
can alleviate torsional stress generated by the movement of
DNA replication forks and transcription complexes, and
can resolve DNA knots and tangles generated during re-
combination and replication (1–6). When type II topoi-
somerases cleave the DNA, they create a four-base stag-
ger with a 5′ overhang. In order to maintain genomic in-
tegrity during this process, active site tyrosine residues co-
valently attach to the newly generated 5′-termini; these co-
valent enzyme-cleaved DNA complexes are referred to as
cleavage complexes (1–6). It is notable that the two cleavage
steps do not occur simultaneously (7–9), and that the anti-
cancer drug etoposide is capable of stabilizing both single
and double-stranded cleavage complexes (Figure 1) (8).
Human cells express two closely related type II enzymes,
topoisomerase II and II. Topoisomerase II is upregu-
lated in proliferating cells and plays essential roles in DNA
replication and chromosome segregation (2,3,6). A recent
study also presents strong evidence that this isoform plays
important roles in transcription (10). Topoisomerase II
concentration is high in all cells irrespective of proliferative
status, and the enzyme has demonstrated roles in transcrip-
tion (11,12). Although it is not essential at the cellular level,
topoisomerase II is critical for the proper development of
the nervous system (13,14).
Beyond their cellular functions, type II topoisomerases
are also the targets for some of the most widely prescribed
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Figure 1. Structure-guided design of an OTI. (A) Schematic illustrating domains of type II topoisomerases used to determine the crystal structure of
human topoisomerase II covalently attached to DNA (green) in the presence of etoposide (orange). Domains pictured are TOPRIM (Top), winged helix
domain (WHD), tower domain (Tow), and exit gate domain (Ex). (B) Schematic of topoisomerase II function. Protein protomer subunits are shown in
blue and gray. T DNA, transport double helix (black); G DNA, gate double helix (green). (C, D) Detail from the crystal structure of a topoisomerase II
cleavage complex with two bound etoposide molecules (orange) stabilizing a double-stranded DNA (green) break; PDB code 3QX3. For clarity, in panel
C, only the C trace of the protein subunits (blue and black lines) and catalytic tyrosines (blue and gray sticks) are shown. In panel D, only the catalytic
tyrosine residues that cleave the DNA are shown. The conventional numbering scheme used for DNA cleavage complexes formed by type II topoisomerases
is shown. The enzyme cleaves between the -1 and the +1 on each strand. The numbering on the two strands in the double helix is differentiated by the
presence or absence of asterisks. The catalytic tyrosine residues are covalently attached to the DNA at the +1 positions. (E, F) Model of a cleavage complex
with one bound etoposidemolecule stabilizing a single-strandedDNAbreak. The cleavedDNA strand is indicated by asterisks. The protein subunits shown
are the same as those in C and D. (G) Chemical (left) and modeled (right) structure of the etoposide core (DEPT) linked to the pyrimidine base. (H) OTI28
(orange strand) modeled with the modified cytosine base in the +5* position, stabilizing DNA scission at the 23–24 site (–1 to +1) on the cleaved target
strand (green). Structural figures were drawn with Pymol (The PyMOLMolecular Graphics System, Version 1.8 Schro¨dinger, LLC).
anticancer drugs in the world (2,15–17). Drugs such as
etoposide, doxorubicin, and mitoxantrone are used rou-
tinely to treat breast cancer, germline cancers, leukemias,
lymphomas, and a variety of solid tumors (17). These drugs
stabilize the cleavage complex by intercalating into the
cleavedDNA scissile bonds, thereby blocking ligation of the
DNA (7,18). When DNA replication forks or other track-
ing systems encounter these drug-stabilized enzyme–DNA
complexes, they convert the transient DNA breaks into
chromosomal damage that requires DNA repair pathways
to restore the double helix (2,15–17). Due to their mecha-
nism of action, these drugs are referred to as topoisomerase
II poisons.
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Despite the fact that all human cells express one or
both topoisomerase II isoforms, topoisomerase II-targeting
drugs are efficacious against cancer cells primarily for three
reasons. First, because cancer cells are generally highly pro-
liferative, they express high levels of topoisomerase II
(3,17,19), leading to the creation of more drug-stabilized
cleavage complexes. Second, because of the high metabolic
rate of cancer cells, replication forks and transcription com-
plexes constantly move along the DNA, making it more
likely that they will convert cleavage complexes to perma-
nent DNA breaks (20). Third, due to impaired cell cycle
checkpoints and DNA damage repair pathways in many
cancers, malignant cells often are more susceptible to the
DNA damage caused by topoisomerase II-targeted drugs
(17,21).
Treatment with topoisomerase II poisons, however, is ac-
companied by a variety of mechanism-induced (i.e., topoi-
somerase II-generated) toxicities. These arise because of the
difficulty of targeting drugs such as etoposide specifically to
cancer cells (2,15,17,22) and because all cell types express
one or both topoisomerase II isoforms (4,6). Furthermore,
approximately 2–3% of patients treated with regimens that
include topoisomerase II-targeted drugs, such as etoposide,
mitoxantrone, and doxorubicin, go on to develop secondary
leukemias. Primarily, these malignancies are acute myeloge-
nous leukemias (AMLs) associated with rearrangements in
the mixed lineage leukemia (MLL) gene at chromosomal
band 11q23, and acute promyelocytic leukemias (APLs) as-
sociated with rearrangements between the promyelocytic
leukemia (PML) gene and the retinoic acid receptor 
(RARA) gene [t(15;17)(q22;q12)] (17,23,24). Although the
specific mechanism by which drug-induced topoisomerase
II-mediated DNA cleavage triggers the leukemic transloca-
tion is controversial, considerable circumstantial evidence
suggests that sites cleaved by the enzyme go on to generate
the translocation breakpoint (10,17,23–26).
A number of cancers are associated with the presence
of a driver oncogene that is generated by a mutation or
translocation in the DNA (27–29). The ability to rapidly se-
quence patients’ DNA affords a potential opportunity to
develop new generations of topoisomerase II poisons that
specifically target the driver mutations in cancer cells of af-
fected individuals. This could introduceDNA strand breaks
specifically in the oncogene or could generate cleavage com-
plexes that act as roadblocks for transcription. In either
case, disruption of the driver oncogene or interference with
its transcription could potentially kill malignant cells that
are dependent on the resulting oncoprotein. Consequently,
this strategy could result in treatments that are cytotoxic to-
ward cancer but display limited action against normal cells.
As a first step toward developing sequence-specific topoi-
somerase II poisons with potential for use as anticancer
agents, we covalently coupled the active core of etoposide
to oligonucleotides centered on a topoisomerase II cleav-
age site in the PML gene. The initial sequence used for
this OTI was identified as part of the translocation break-
point of a patient with APL who had been treated with
mitoxantrone for progressive multiple sclerosis (30). Sub-
sequent OTI sequences were derived from the observed
APL breakpoint between PML and RARA. Results indi-
cate that OTIs can be used to direct the sites of etoposide-
induced DNA cleavage mediated by topoisomerase II and
topoisomerase II. Furthermore, OTIs directed against the
PML-RARA breakpoint displayed cleavage specificity for
oligonucleotides with the translocation sequence over those
with sequences matching either parental gene. These stud-
ies demonstrate the feasibility of using oligonucleotides to
direct topoisomerase II-mediated DNA cleavage to specific
sites in the genome.
MATERIALS AND METHODS
Molecular modeling
To guide the placement and length of the chemical linker
that joined the active demethylepipodophyllotoxin (DEPT)
core of etoposide to the modified base in the oligonu-
cleotides, structures of OTI complexes were modeled using
Coot (31), MOE (32), and Maestro (Schro¨dinger Release
February 2017: Maestro, Schro¨dinger, LLC, New York,
NY, 2017). Models were based on the crystal structures of
the human topoisomerase II and topoisomerase II cleav-
age complexes withDNAand two etoposidemolecules (one
at each scissile bond) (PDB code: 3QX3 (18) and PDB code:
5GWK (33), respectively), and the Staphylococcus aureus
gyrase–DNA complex with one etoposide molecule (PDB
code: 5CDP) (34) (Supplementary Figure S1). The posi-
tions of the etoposide molecules in the DNA complexes
with human and bacterial enzymes are essentially the same
(Supplementary Figure S1).
With two etoposide molecules bound (one at each scissile
bond), the DNA gate seems to be wedged open with a rel-
atively small area buried between the two protein subunits
at the DNA gate (18,34) (Supplementary Figure S2). How-
ever, a much larger area is buried between the two subunits
at theDNA gate (Supplementary Figure S2) in the S. aureus
DNA gyrase with one etoposide bound, and the common
CRsym conformation is observed (34). Given that this con-
formation has also been observed with eukaryotic type IIA
topoisomerases (34,35), the subunits in our modeled topoi-
somerase II complex with one etoposide were modeled in
a CRsym conformation (Figure 1; notice movement of cat-
alytic tyrosines between complex with one and two etopo-
sides relative to movement of the two subunits).
The alkyne moiety of the linker on the C5 position of the
modified base projects ∼2.6 A˚ further than the methyl on
the C5 position of a thymine or a methylated cytosine (Sup-
plementary Figure S2A). In modeling studies, the modified
base was covalently attached to DEPT with a linker (Fig-
ures 1E, F and 2), and was modeled at four positions ad-
jacent to the cleavage site on each strand (Supplementary
Figure S3): −2, −1, +1 and +2 on the cleaved strand, and
+3*, +4*, +5* and +6* on the non-cleaved (or OTI strand.
The rod-like alkyne moiety was observed to clash with pro-
tein residues when positioned on the cleaved strand at the
−2, −1, +1 or +2 positions. However, modeling the rod-
like alkyne moiety on the uncleaved strand at the +3*, +4*,
+5* or +6* position did not result in any clashes (Supple-
mentary Figure S3). These models indicate that cleavage is
most likely to occur on the target strand rather than theOTI
strand itself. Two different lengths of linkers were modeled,
but a much longer linker (Figure 1E, F) was needed to en-
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Figure 2. Schematic of the synthesis of OTIs. The synthesis of OTI28 (7) is shown as an example. DEPT (1) was protected with carboxybenzyl (Cbz)
at the 4′-OH using benzyl chloroformate and triethylamine in dichloromethane to yield 2. The 4-OH of 2 was reacted with monotosylated diethylene
glycol using boron trifluoride etherate in dichloromethane at –20◦C to generate 3a–b as a mixture of two epimers. Removal of the Cbz protecting group
under hydrogenation reaction conditions with Pd/C in ethanol resulted in 4a–b. The tosyl group was displaced with sodium azide in dimethyl formamide
at 60◦C to generate 5a–b as a mixture of two epimers. The desired azide coupling partner 5a was purified as a single epimer by chiral chromatography.
Copper-catalyzed click chemistry was used to couple 5a to oligonucleotide 6 (which included an alkyne-modified cytosine at position 28) to yield OTI28
(7).
able the linked etoposide core to reach back to the binding
site in the DNA from the +3*, +4*, +5* or +6* positions.
Chemistry
A scheme for the synthesis of OTIs linked to the etopo-
side core is shown in Figure 2. On the basis of the molecu-
lar modeling results, an 8-carbon linker was utilized, which
consisted of a terminal alkyne moiety attached to the C5
position of a cytosine or thymine residue to attach an azide-
modified 4′-DEPT (1) via copper-catalyzed click chemistry.
Synthesis of the activated etoposide core, shown in the
top portion of Figure 2, started with commercially avail-
able DEPT (1) (ABCAMBiochemicals). Compound 1 sub-
sequently was protected with carboxybenzyl (Cbz) at the
4′-OH using benzyl chloroformate and triethylamine in
dichloromethane (20). The desired product 2 was obtained
in 91% isolated yield. The 4-OH of 2 was reacted with
monotosylated diethylene glycol (21) using boron trifluo-
ride etherate in dichloromethane at −20◦C to generate 3a–
b in 72% yield as a mixture of two epimers. Removal of the
Cbz protecting group under hydrogenation reaction condi-
tions with Pd/C in ethyl acetate resulted in 4a–b in 94%
yield. The tosyl group was displaced with sodium azide in
dimethyl formamide at 60◦C and generated 5a–b in 67%
yield as a mixture of two epimers. The desired azide cou-
pling partner 5a was purified as a single epimer by chiral
chromatography.
The synthesis of OTIs, exemplified by 7, is shown
in the bottom portion of Figure 2. Oligonucleotide 6,
which included an alkyne-modified cytosine (purchased
from Jena Biosciences) at position 28, was synthesized
by well-established solid phase methods. Copper-catalyzed
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click chemistry was employed to synthesize OTI28 (7)
using a preformed complex of copper bromide and
Tris(benzyltriazolylmethyl)amine (TBTA) in a mixture of
dimethyl sulfoxide (DMSO), tert-butanol and water. A fi-
nal isolated yield of 46%was obtained after HPLC purifica-
tion. Subsequent OTIs were synthesized in a similarmanner
with an alkyne-modified thymine (Integrated DNA Tech-
nologies) at positions 23, 29 or 33 as the point of attachment
for the linked DEPT, yielding OTI23, OTI29, and OTI33,
respectively. Three additional OTIs of different lengths, a
50-mer, 30-mer and 20-mer, were directed against a patient-
derived PML-RARA breakpoint sequence (see below). The
linked etoposide core in the 50-mer was positioned at the
same site as OTI29.
Data confirming the structure and purity of all OTIs and
intermediate small molecules can be found in the Appendix.
Purity ranged from 90% to 99.9%.
Enzymes and materials
Recombinant wild-type human topoisomerase II and
topoisomerase II and wild-type yeast topoisomerase II
and the etoposide-resistant H1011Y mutant yeast type
II enzyme were expressed in Saccharomyces cerevisiae
JEL-1top1 and purified as described previously (36–39).
The drug resistance mutation was originally published as
H1012Y (38). The numbering of the mutation was changed
to H1011Y in 2001 (40) to accommodate a reported error
in the original amino acid sequence of S. cerevisiae topoi-
somerase II (41). Human enzymes were stored at −80◦C
as 1.5 mg/ml stocks in 50 mM Tris–HCl, pH 7.9, 0.1 mM
EDTA, 750 mMKCl, and 40% glycerol, and yeast enzymes
were stored as 2 mg/ml stocks in a similar buffer. Analyti-
cal grade etoposide was purchased from Sigma-Aldrich and
stored at room temperature as a 40 mM stock solution in
100% DMSO.
Oligonucleotides and OTIs
Three DNA sequences were used to create a series of
oligonucleotide duplexes. The first sequence was a 50-mer
that encompassed bases 1461–1510 of intron 6 of PML,
and contained a previously identified, 8-base topoiso-
merase II cleavage hotspot (bases 1482–1489) associated
with the generation of therapy-related APLs (t-APL) (42).
The hotspot contains a strong topoisomerase II-mediated
cleavage site that corresponds to position 24–25 on the top
(or target) strand of the oligonucleotide and to 26–27 on
the bottom strand (either an unmodified oligonucleotide




OTI28, OTI29, OTI33, and OTI23 had the same sequence
as the PML 50-mer bottom strand, except that the active
core of etoposide (DEPT) was linked at positions 28,
29, 33 and 23, respectively. A 50-mer bottom strand that
contained the linker with no attached drug (LIN28) or
a tetrahydrofuran (Eurofins MWG Operon) abasic site
analog (AP28) at position 28 also were synthesized.
The second sequence was a 50-mer that spanned
a previously identified translocation between PML
and RARA in a patient with t-APL (30). Top strand:
5′-CTTTGTTCCTCATTCTGACTGAGCCCTA/GT
CTGCCATCCTAACCTTCCAT-3′, made up of bases
1461–1488 of intron 6 of PML (before the slash) and bases
12039–12060 of intron 2 of RARA (after the slash) The
bottom strand was fully complementary. Bottom strand:
5′-ATGGAAGGTTAGGATGGCAGAC\TAGGGCTC
AGTCAGAATGAGGAACAAAG-3′. Sequences from
RARA are located to the left of the backslash and sequences
from PML are located to the right of the backslash. A 50-
mer OTI with the bottom strand sequence was synthesized
and contained a linked DEPT at position 29. Two addi-
tional OTIs based on the same sequence, a 30-mer (5′-TAA
GACTGACTCGGGATCAGACGGTAGGAT-3′) and
a 20-mer (5-CTGACTCGGGATCAGACGGT-3′), were
synthesized. These sequences contained 10 or 15 fewer
bases from each of the 5′- and 3′-termini of the 50-mer,
respectively.
The third sequence was a 50-mer that corresponded
to the parental RARA sequence that spanned a
patient-derived translocation (at 12038–12039, corre-
sponding to 28–29 on the oligonucleotide) and that
included bases 12011–12060 of intron 2. Top strand:
5′-CAGAAAGGGGCAACTTCATCAGACACCCG
TCTGCCATCCTAACCTTCCAT-3′. All the non-OTI
oligonucleotides were synthesized by Sigma-Aldrich unless
specified.
DNA cleavage
DNA cleavage reactions were carried out by a modification
of the procedure of Deweese et al. (43). The top (target)
strand of each double-stranded oligonucleotide was labeled
on its 5′-terminus in 30 l reactions containing 200 pmol
of oligonucleotide, 1 l of T4 polynucleotide kinase (PNK)
(New England BioLabs), 3 l of T4 PNK buffer as sup-
plied by the manufacturer, and 2 l of [ -32P]ATP (∼5000
Ci/mmol, Perkin Elmer). Reactions were incubated at 37◦C
for 60 min, with an additional 1 l of T4 PNK added after
the first 30 min. Radiolabeled oligonucleotides were puri-
fied with QiagenMini Quick Spin columns according to the
manufacturer’s instructions. Top/target and bottom/OTI
oligonucleotides were annealed by incubating them at a 1:1
ratio (0.5 pmol/l) at 70◦C for 10 min, followed by a grad-
ual cool down to room temperature.
DNA cleavage reaction mixtures contained 2 pmol
of double-stranded oligonucleotides and 440 nM human
topoisomerase II, 415 nM human topoisomerase II, 600
nM wild-type yeast topoisomerase II, or 1340 nMH1011Y
mutant yeast topoisomerase II in a final volume of 20 l
of human [10 mM Tris–HCl pH 7.9, 5 mM MgCl2, 100
mM KCl, 0.1 mM EDTA and 2.5% (v/v) glycerol] or yeast
[50 mM Tris–HCl pH 7.9, 25 mM MgCl2, 500 mM NaCl,
0.5 mM NaEDTA, pH 8.0, 12.5% (v/v) glycerol] cleavage
buffer. (Levels of yeast enzymes in DNA cleavage assays
were adjusted to yield similar levels of background DNA
cleavage.) Reactions were initiated by the addition of en-
zyme. Samples were incubated at 37◦C for 10 min (topoi-
somerase II or yeast topoisomerase II) or 1 min (topoi-
somerase II), and reactions were stopped by the addi-
tion of 2 l of 10% sodium dodecyl sulfate (SDS) and 2
Nucleic Acids Research, 2018, Vol. 46, No. 5 2223
Figure 3. An oligonucleotide-linked etoposide core increases topoisomerase II-mediated DNA cleavage. (A) The central 30 base pairs of a double stranded
50-mer oligonucleotide sequence corresponding to bases 1471–1500 (top strand) of PML intron 6 is shown. The yellow box denotes the position of the
tethered etoposide core and linker moieties on OTI28 or LIN28. Arrows indicate sites of DNA cleavage induced by free etoposide (blue) or OTI28 (yellow).
(B) Comparison ofDNAcleavagemediated by human topoisomerase II (hTII, left) and topoisomerase II (hTII, right) of the radiolabeled, unmodified
PML top strand hybridized to an unmodified PML bottom strand in the presence of free etoposide or hybridized to OTI28 (bottom strand). For each
gel, lane 1 contains the unmodified PML oligonucleotide. Lanes 2–5 contain the unmodified PML duplex treated with 0–500 M free etoposide. Lanes 7
and 8 contain the unmodified PML top strand hybridized with OTI28. Lanes 10 and 11 contain the unmodified top strand duplexed with LIN28 (bottom
strand oligonucleotide that contains the linker at position 28 with no attached etoposide core). Lanes 6, 9, and 12 contain reference (R) oligonucleotides
that were 24, 23 and 19 bases in length. Gels are representative of at least three independent experiments. (C) Quantification of the relative levels of DNA
cleavage mediated by topoisomerase II (left) and topoisomerase II (right). DNA cleavage at each site was normalized to the cleavage observed at site
24–25 in reactions containing unmodified duplex in the absence of etoposide (lane 2). Cleavage results of the unmodified duplex in the presence of 500 M
free etoposide are shown in blue (lane 5) and those with an unmodified top strand hybridized to OTI28 are shown in yellow (lane 8). Error bars represent
the standard error of the mean of an average of two to five independent experiments. Significance was determined by paired t-tests. P-values are indicated
by asterisks (*P < 0.05; **P < 0.005; ***P < 0.0005).
l of 250 mM disodium ethylenediaminetetraacetic acid
(Na2EDTA). Samples were incubated with proteinase K
(2 l of 0.8 mg/ml) for 30 min at 37◦C to digest the type
II enzyme. DNA cleavage products were precipitated with
ethanol, mixed with 5l of 80% (v/v) formamide, 10%TBE
(100 mM Tris–borate and 2 mM EDTA), and 10% agarose
loading dye [60% sucrose (w/v), 10 mM Tris–HCl, 0.5%
bromophenol blue, 0.5% xylene cyanol] and heated to 75◦C
for 2 min. DNA samples were resolved on 14% denaturing
polyacrylamide gels and were visualized and quantified us-
ing a Bio-Rad Molecular Imager.
All double-stranded oligonucleotides contained unmod-
ified (non-OTI) top/target strands that were radiolabeled
at the 5′ end. Bottom strands were either unmodified (non-
OTI) or contained linked etoposide core (OTI), linker alone,
or a tetrahydrofuran (abasic site analog). In some cases,
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unmodified double-stranded oligonucleotides were treated
with 0–500 M etoposide.
DNA ligation
DNA ligation assays were carried out with topoisomerase
II by a modification of the procedure of Byl et al. (44).
DNA cleavage/ligation equilibria were established as in the
previous section. Reactions contained either an unmodi-
fied double-stranded oligonucleotide in the presence of 500
M etoposide or an unmodified top (i.e. target) strand hy-
bridized to an OTI28 bottom strand. Ligation was initi-
ated by placing the reaction mixtures on ice. The tempera-
ture shift allows ligation but prevents the formation of new
cleavage complexes (45). Ligation reactionswere stopped by
the addition of 2 l of 10% SDS followed by 2 l of 250
mM Na2EDTA. Samples were processed and analyzed as
described above. The percent DNA cleavage at time zero
was set to 100%, and the rate of ligation was determined
by quantifying the loss of cleaved DNA over time.
Persistence of cleavage complexes
DNA cleavage/ligation equilibria were established using
topoisomerase II as described above. Persistence reactions
were carried out by a modification of the procedure of Ban-
dele and Osheroff (46). Reactions contained either an un-
modified double-stranded oligonucleotide in the presence
of 500 M etoposide or an unmodified top strand hy-
bridized to an OTI28 bottom strand. Assay mixtures were
diluted 20-fold with cleavage buffer and incubated at 37◦C
for up to 120 min. Reactions were stopped as above, and
samples were processed and analyzed as described above.
The percent DNA cleavage at time zero was set to 100%,
and the stability of the cleavage complexes was determined
by quantifying the loss of cleaved DNA over time.
RESULTS
Structure-based design of OTIs that contain the core of
etoposide
When cells are treated with etoposide, the drug induces
topoisomerase II-mediated DNA cleavage at millions of
sites throughout the human genome (10). Therefore, in an
effort to design an etoposide-based compound with speci-
ficity for cancer-associated DNA sequences, we covalently
attached the active core of etoposide (DEPT) to a series
of oligonucleotides (Figures 1 and 2). DEPT lacks the C4
sugar moiety of etoposide but retains a C4 hydroxyl group
that can be activated for coupling reactions. As determined
by saturation transfer difference nuclear magnetic reso-
nance spectroscopy, the sugar moiety does not interact with
topoisomerase II (47,48). Furthermore, its removal has a
negligible effect on the activity of the drug toward the type
II enzyme (47,48). For the purposes of the paper, the linked
DEPT will be referred to as the etoposide core.
OTIs were designed to generate single-stranded, topoi-
somerase II-mediated cleavage on the strand opposite the
etoposide core attachment site (Figure 1) (8). To this end,
crystal structures of human topoisomerase II (18) and II
(33) with two etoposide molecules and the bacterial Staphy-
lococcus aureus DNA gyrase with one or two etoposide
molecules (34) served as the basis formodeling studies (Sup-
plementary Figure S1). As a result of these studies, a linker
consisting of a terminal alkyne moiety was attached to the
C5 position of a cytosine or thymine residue and was cou-
pled to a 4-azide-modifiedDEPT via copper-catalyzed click
chemistry (Figure 2). The modeling studies indicated that
the linked DEPT was capable of intercalating into a cleaved
site on the opposite strand (shown for OTI28 in Figures 1
and 4 and Supplementary Figures S3 and S4).
AnOTI directed against thePML gene enhances DNA cleav-
age mediated by human type II topoisomerases
As a proof of concept that a covalently attached etoposide
core can function as a sequence-specific topoisomerase II
poison, we designed an initial OTI (OTI28) that utilized
a DNA sequence spanning a strong drug-induced topoiso-
merase II cleavage hotspot within intron 6 of the PML gene
(bases 1482–1489) (42). This cleavage hotspot is also present
in the t(15;17) translocation of a patient with APL who had
been treated with mitoxantrone (30). The interaction of an
OTI that spanned theAPL breakpoint sequence with topoi-
somerase II will be discussed in a later section.
The sequence of the central 30 nucleotides of the 50-
base pair-oligonucleotide used for the initial experiments
(bases 1461–1510) is shown in Figure 3A. When the
unmodified oligonucleotide duplex (radiolabeled on its
top/target strand) was treated with free etoposide in the
presence of topoisomerase II, several strong DNA cleav-
age sites were observed (Figure 3). The cleavage site be-
tween bases 24–25 (1484–1485) is also a strong site for mi-
toxantrone and is believed to be the hotspot that results
in ∼50% of the t(15;17) translocations observed in patients
with therapy-related APLs following treatment with mitox-
antrone (17,24,30,42,49).
To examine the effects of a linked drug on topoisomerase
II-mediated DNA cleavage of this sequence, the active core
of etoposide was covalently attached to cytosine 28 on the
bottom strand (Figure 3A) through a flexible linker as de-
scribed above. On the basis of modeling studies, the teth-
ered drug moiety should be able to intercalate into the scis-
sile bond between bases 24–25, stabilizing cleavage at that
site (Figures 1 and 4A). As seen in Figure 3, this was the
case when the unmodified bottom strand was replaced with
the drug-linked oligonucleotide (OTI28, bottom strand).
Topoisomerase II cleaved at this position (between bases
24–25 on the top strand) at levels that were even higher than
those observed in the unmodified duplex in the presence
of 500 M free etoposide. High enzyme-mediated cleavage
was also observed one base away (between bases 23 and 24
on the top strand), although at slightly lower levels than at
site 24–25. Drug insertion at this position is also supported
by modeling studies (Figure 4B).
Four additional points should be noted regarding the
data shown for topoisomerase II (Figure 3B, C; left): first,
no DNA cleavage was observed in the absence of topoi-
somerase II (lane 1), indicating that the tethered etopo-
side core does not induce cleavage via a spontaneous chem-
ical reaction. Second, OTI28 did not induce topoisomerase
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Figure 4. Molecular models of DNA cleavage complexes formed with OTI28. Models were based on the crystal structure of topoisomerase II (34). (A)
Cleavage between bases 24–25 is depicted on the target (top) strand (green). (B) Cleavage between bases 23–24 is depicted on the target strand (green). The
bottom (OTI) strand is shown in orange. The tethered etoposide core is shown in yellow (carbons, yellow; nitrogen, blue; oxygen, red). A C trace is shown
for the two topoisomerase II subunits (blue and black lines) in the top panels. The bottom panels include a semi-transparent molecular surface, illustrating
that the linker does not clash with the protein. The sequence diagram (middle) shows the position of the tethered etoposide core on OTI28 (yellow box).
Black arrows indicate the cleavage sites.
II-mediated cleavage at any of the other strong cleavage
sites induced by free etoposide (compare lanes 8 and 5).
This finding suggests that the specificity of the etoposide
core can be constrained by its covalent attachment to an
oligonucleotide. Third, some minor sites of topoisomerase
II-mediatedDNA cleavage with OTI28 were not predicted
by our modeling studies (Figures 1 and 4). These sites were
not related to the conditions utilized to anneal the OTIs
to their complementary strand. Similar DNA cleavage pat-
terns were observed when annealing temperatures were var-
ied by 30◦C and cooling rates differed over an 8-fold range
(Supplementary Figure S5). These findings suggest that the
presence of the drug may subtly alter the structure of the
duplex that affects its interaction with topoisomerase II.
Lastly, no enzyme-mediated DNA cleavage was observed
when the bottom strand was replaced with an oligonu-
cleotide that contained the linker alone (i.e. a linker with
no attached drug moiety; lane 11). This provides strong ev-
idence that it is the presence of the etoposide core rather
than the linker alone on the oligonucleotide that enhances
topoisomerase II-mediated DNA cleavage.
Results similar to those with topoisomerase II also were
observed with topoisomerase II (Figure 3B, C; right). The
same two strong sites of enzyme-mediated DNA cleavage
were observed in a duplex containing OTI28. Once again,
scission at both cleavage sites (24–25, 23–24) was higher
than that seen in the unmodified duplex in the presence of
500 M free etoposide (compare lanes 8 and 5). However,
cleavage at 23–24 was similar to that seen at 24–25. Finally,
as seen with the  isoform, topoisomerase II did not cleave
a duplex with a bottom strand that contained a linker but
no tethered etoposide core at position 28 (lane 11).
To further characterize the mechanism of enzyme-
mediated DNA cleavage induced by the OTI, the effects of
the tethered etoposide core on rates of DNA ligation medi-
ated by topoisomerase II were compared to those of free
etoposide on an unmodified duplex oligonucleotide. Similar
inhibition of religation was observed for both the tethered
and the untethered drug (Figure 5A). Thus, like free etopo-
side, the OTI increases levels of cleavage complexes by in-
hibiting ligation of the cut DNA.
In addition, cleavage complexes formed with OTI28 ver-
sus free etoposide persisted for similar lengths of time (Fig-
ure 5B) following 20-fold dilution of the reaction mixtures.
Therefore, the OTI appears to stabilize cleavage complexes
to a comparable extent as the free etoposide. These findings
further suggest that the effects of tethered etoposide core
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Figure 5. OTI28 inhibits DNA ligation and stabilizes cleavage complexes similarly to free etoposide. (A) Enzyme-mediated ligation ofDNA. (B) Persistence
of cleavage complexes. For both A and B, cleavage results of the unmodified PML duplex in the presence of 500 M free etoposide are shown in blue and
those with an unmodified PML top/target strand hybridized to OTI28 are shown in yellow. Error bars represent the standard deviation of at least three
independent experiments.
within the cleavage complex produce similar effects to the
free drug.
DNA lesions have the capacity to act as topoisomerase II
poisons. Abasic sites are among the most effective DNA le-
sions at inducing topoisomerase II-mediatedDNA cleavage
(39,50,51). Thus, to provide further evidence that the effects
of OTI28 were mediated by the tethered drug moiety as op-
posed to a distortion in the double helix, we synthesized an
oligonucleotide that replaced the cytosine-linker-etoposide
core construct at position 28 with a tetrahydrofuran abasic
site analog (AP28). DNA cleavage results are shown in Fig-
ure 6. The abasic site induced lower levels of cleavage than
OTI28, with the major site of DNA cleavage (position 19–
20) being five bases away from that of OTI28 (24–25) (com-
pare lanes 7 to 5). The differences in the cleavage patterns
obtained with AP28 and OTI28 provide additional strong
evidence that DNA cleavage induced by OTI28 is due to
the actions of the tethered etoposide core by type II topoi-
somerases and not to a distortion or lesion in the helix at
the site of drug attachment.
Finally, the ability of OTI28 to induce DNA cleavage
mediated by an etoposide-resistant type II topoisomerase
was assessed. The yeast topoisomerase II H1011Y mutant
(52) was used for these experiments for two reasons. First,
target-based resistance to topoisomerase II-targeted drugs
is generally associated with the loss of one enzyme allele or
the deletion of nuclear localization signals (53,54). Conse-
quently, point mutations that impart etoposide resistance to
human type II topoisomerases have not been well described
or characterized. Second, yeast topoisomerase II is highly
sensitive to etoposide, and the H1011Y mutant is the only
type II enzyme that has been shown to be etoposide resis-
tant due to a reduced affinity for the drug (55).
As seen in Figure 7, yeast topoisomerase II H1011Y is
∼4-fold resistant to the tethered etoposide core in OTI28 as
compared to the wild-type enzyme. This result is consistent
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Figure 6. An oligonucleotide with an abasic site analog at position 28 gen-
erates a different DNA cleavage pattern than does OTI28. Lanes 1–3 con-
tain a radiolabeled unmodified PML top/target strand hybridized to an
unmodified PML bottom strand in the absence of enzyme, or in the pres-
ence of enzyme and 0–500 M free etoposide. Lanes 4 and 5 contain a ra-
diolabeledPML top strand hybridized with OTI28 (bottom strand). Lanes
6 and 7 contain a radiolabeled unmodified PML top strand hybridized to
a bottom strand oligonucleotide containing an abasic site analog at po-
sition 28 (AP28). Lane 8 contains reference (R) oligonucleotides that are
24, 23 and 19 bases in length. The gel is representative of at least three
independent experiments.
with the resistance of the mutant enzyme to free etoposide
(52).
Taken together, the above experiments provide strong ev-
idence that the DNA cleavage induced by OTI28 is due to
the presence of the tethered etoposide core.
OTIs enhance topoisomerase II-mediated DNA cleavage in a
sequence-dependent manner
As described above, the major site of topoisomerase II-
mediated DNA cleavage on the top/target strand induced
by OTI28 was located at a position two bases away and
opposite the tethered etoposide core (site 24–25). To deter-
mine whether OTIs generate a predictable pattern of cleav-
age, we shifted the location of the tethered etoposide core to
three additional locations along the sequence of the bottom
oligonucleotide: positions 29 (OTI29), 33 (OTI33) and 23
(OTI23) (Figure 8A). These locations were chosen to see if it
was possible to move the major site of DNA cleavage to the
second-strongest site of scission induced by OTI28 (site 23–
24), to the site of secondary DNA cleavage induced when
free etoposide was added to an unmodified duplex (site 19–
20), and to a site that was not cleaved in the presence of free
etoposide (site 29–30), respectively.
In all three cases, strong topoisomerase II-mediated
DNA cleavage induced by the new OTIs was observed two
bases away opposite the drug location at the predicted sites
Figure 7. OTI28 induces lower levels of DNA cleavage mediated by an
etoposide-resistant mutant yeast topoisomerase II (H1011Y) as compared
to wild-type yeast topoisomerase II. Quantification of the relative levels
of enzyme-mediated DNA cleavage at site 24–25 (indicated as the band
labeled 24 in the inset) mediated by wild-type (yTop2WT) and H1011Y
mutant (yTop2H1011Y) yeast topoisomerase II on an unmodified PML
top strand hybridized to OTI28 (graph: +enz, red; inset: +WT, +H1011Y).
DNA cleavage is normalized to background levels of DNA when no en-
zyme is present (graph: -enz, blue; inset: -WT, -H1011Y). Error bars repre-
sent the standard deviation of three independent experiments. Significance
was determined by a paired t-test.P-values are indicated by asterisks (***P
< 0.0005).
described above (Figure 8B; left). As with OTI28, some of
the new OTIs also induced DNA scission at sites that were
not predicted by our modeling studies (Figures 1 and 4).
However, these sites were all in the vicinity of the predicted
sites of cleavage. Similar sites of DNA cleavage were ob-
tained with these OTIs and topoisomerase II (Figure 8B;
right).
Two important conclusions can be drawn from these
studies. First, OTIs can be used to induce DNA cleavage, at
least in part, in a predictable manner. Second, sites of cleav-
age can bemoved to sequences not normally associatedwith
the actions of free etoposide (Figures 3A and 8A, B). Thus,
the use of OTIs is not restricted to pre-existing etoposide-
induced sites of cleavage, implying that it may be possible to
design OTIs against almost any patient sequence associated
with a cancer mutation or chromosomal breakpoint.
OTIs can be directed against a t(15;17) translocation break-
point seen in a patient with APL
One of the goals in characterizing OTIs is to determine if
it would be possible to target them to cancer-specific se-
quences present in malignant cells. Therefore, having es-
tablished the proof of principle that OTIs can be used to
direct the location of etoposide-induced topoisomerase II-
mediated DNA cleavage, we designed an OTI against a
2228 Nucleic Acids Research, 2018, Vol. 46, No. 5
Figure 8. Moving the position of the linked etoposide core along the bottom strand (OTI) sequence alters the topoisomerase II-mediated cleavage pattern
of the top strand. (A) Sequences of the top/target and bottom PML strands are shown. The different-colored boxes indicate the position of the tethered
etoposide core in each OTI (bottom strand), including OTI28 (yellow), OTI29 (orange), OTI33 (green), and OTI23 (purple). Arrows indicate the cleavage
sites induced by each OTI (shown by corresponding colors). Large arrows indicate the major site of cleavage. T and B (first column) indicate top and
bottom strands, respectively. (B) Comparison of DNA cleavage mediated by human topoisomerase II (hTII, left) and topoisomerase II (hTII, right)
of the radiolabeled, unmodified PML top strand hybridized to an unmodified PML bottom strand in the presence of 0–500 M free etoposide (lanes 2–3)
or hybridized to the bottom strands OTI28 (lanes 5–6), OTI29 (lanes 8–9), OTI33 (lanes 11–12), or OTI23 (lanes 14–15). For each gel, lane 1 contains an
unmodified PML duplex. Reference (R) oligonucleotides are 24, 23, 20 and 19 bases long. Gels are representative of at least three independent experiments.
t(15;17) chromosomal translocation (breakpoint at 1484–
1485 in PML and 12034–12035 in RARA) in a patient with
t-APL (Figure 9A) (30). This sequence was chosen because
it encompasses the site of cleavage in thePML gene induced
by OTI28 (Figure 3). Initial studies with the translocation
sequence utilized a 50-base pair oligonucleotide that was
comprised of bases 1461–1488 of intron 6 of PML (Figure
9A; blue) and 12039–12060 of intron 2 of RARA (Figure
9A; orange).
First, the unmodified breakpoint oligonucleotide duplex
was treated with free etoposide (0–500 M) in the presence
of topoisomerase II, and several cleavage sites were ob-
served (Figure 9B, C; left). The strongest of these sites were
observed at positions 24–25, 25–26 and 19–20 on the top
strand (lane 5), in order of decreasing strength of cleavage.
Second, the unmodified target strandwas hybridizedwith
a complementary 50-base OTI in which the tethered etopo-
side core was located at the equivalent position in the PML
gene as OTI29 (Figure 9A). As predicted, this OTI induced
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Figure 9. OTIs designed against a patient-observed PML-RARA translocation increase DNA cleavage mediated by human type II topoisomerases. (A)
Sequences of the top and bottom strands of each PML-RARA duplex are shown. The blue portion corresponds to the segment derived from the PML
gene, and the orange portion corresponds to the segment derived from the RARA gene. The yellow box indicates the position of the tethered etoposide
core on each OTI (bottom strand). The OTIs were 50, 30 or 20 bases in length (black lines below the diagram). Arrows indicate sites of DNA cleavage
induced by free etoposide (blue) and the translocation OTIs (yellow). (B) Comparison of DNA cleavage mediated by human topoisomerase II (hTII,
left) and topoisomerase II (hTII, right) of the radiolabeled, unmodified PML-RARA top/target strand hybridized to an unmodified PML-RARA
bottom strand in the presence of free etoposide or of the radiolabeled PML-RARA top strand hybridized to a 50-mer, 30-mer or 20-mer PML-RARA
OTI bottom strand. Lanes 1–5 contain the unmodified PML-RARA duplex in the absence of enzyme, or in the presence of enzyme and 0–500 M free
etoposide. Lanes 7 and 8 contain the unmodified PML-RARA top strand hybridized with the 50-mer OTI. Lanes 10 and 11 contain the unmodified top
strand hybridized with the 30-mer OTI. Lanes 13 and 14 contain the unmodified top strand hybridized with the 20-mer OTI. Lanes 6, 10, 13, and 15 contain
reference (R) oligonucleotides 24, 23, 20 and 19 bases in length. Gels are representative of at least three independent experiments. (C) Quantification of the
relative levels of enzyme-mediated DNA cleavage. DNA cleavage at each site is normalized to the cleavage observed at site 24–25 in reactions containing
an unmodified duplex in the absence of etoposide (lane 2). Results with unmodified PML–RARA duplex in the presence of 500 M free etoposide (blue)
or with unmodified top strand hybridized with 50-mer OTI (yellow), 30-mer OTI (orange), or 20-mer OTI (green) bottom strand are shown. Error bars
represent the standard deviation of at least three independent experiments. Significance was determined by paired t-tests.P-values are indicated by asterisks
(*P < 0.05; **P < 0.005; ***P < 0.0005).
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Figure 10. OTIs that incorporate an APL patient-derived PML-RARA
translocation sequence do not increase DNA cleavage mediated by hu-
man type II topoisomerases when they are hybridized with the parental
PML orRARA sequences. Comparison of DNA cleavage mediated by hu-
man topoisomerase II (hTII) (A) and topoisomerase II (hTII) (B) of
the radiolabeled top strand of an unmodified PML-RARA duplex in the
presence of free etoposide, a radiolabeled, unmodified PML or RARA top
strand hybridized to a PML-RARA bottom strand in the presence of free
etoposide, or a radiolabeled, unmodified PML or RARA top strand hy-
bridized to a 50-mer OTI, a 30-mer OTI, or a 20-mer PML-RARA OTI
bottom strand. For each gel, lanes 1–3 contain unmodified PML-RARA
top/target strand hybridized to the unmodified 50-mer PML-RARA bot-
tom strand, in the absence of enzyme, or in the presence of enzyme
and 0–500 M etoposide. Lanes 4–6 contain unmodified parental PML
top/target strand hybridized to the unmodified 50-mer PML-RARA bot-
tom strand, in the absence of enzyme, or in the presence of enzyme and 0–
500 M etoposide. Lanes 7–12 contain the unmodified parental PML top
strand hybridized to the 50-mer, 30-mer or 20-mer PML-RARA OTI bot-
tom strand in the absence or presence of enzyme. Lanes 14–16 contain un-
modified parentalRARA top strand hybridized to the 50-merPML-RARA
bottom strand, in the absence of enzyme, or in the presence of enzyme and
strong cleavage at position 23–24 (lane 8), at a site two bases
away and opposite the tethered drug. Strong cleavage was
also observed at sites 20–21 and 24–25 (lane 8).
Human type II topoisomerases display a DNA length-
dependence for scission. The enzyme cleaves a 50-mer du-
plex oligonucleotide considerably better than it does a 40-
mer, and little cleavage is seen with oligonucleotides shorter
than a 30-mer (43). However, when one of the two strands is
maintained at a 50-base length, levels of enzyme-mediated
DNA cleavage remain relatively high until the length of the
complementary strand is reduced to ∼20 bases (43). There-
fore, to see if shorter OTIs could still be used to induce high
levels of topoisomerase II-mediated DNA cleavage in the
translocation sequence, we tested a 30-mer version of the
breakpoint OTI in which 10 bases were removed from each
terminus (Figure 9A). High levels of cleavage were main-
tained at sites 23–24 and 19–20; however, cleavage disap-
peared from site 24–25 (Figure 9B,C; lane 12). As predicted,
when the breakpoint OTI was further reduced in size to a
20-mer version, DNA cleavage levels dropped precipitously
(Figure 9B, C; lane 14).
In all respects, results obtained with topoisomerase II
and the chromosomal translocationmodel oligonucleotides
(with either a free or a tethered etoposide core) were similar
to those obtained with topoisomerase II (Figure 9B, C;
right).
Finally, to determine whether the breakpoint OTIs dis-
played specificity for the translocation over the parental
PML and RARA sequences, the 50-mer, 30-mer and 20-
mer breakpoint OTIs were hybridized to 50-mer top strands
of each parental gene. Very low levels of DNA cleavage
were generated by either topoisomerase II (Figure 10A)
or topoisomerase II (Figure 10B) in the PML oligonu-
cleotide (lanes 8, 10 and 12) and no cleavage was observed in
theRARA oligonucleotide with any of the breakpoint OTIs
(lanes 18, 20, 22). This finding suggests that OTIs could po-
tentially be directed to cancer-specific breakpoints without
generating significant levels of DNA cleavage in the wild-
type parental sequences.
DISCUSSION
Etoposide and other topoisomerase II-targeted drugs
are important therapeutics for the treatment of cancer
(1,2,15,17,22,56). Unfortunately, the induction of topoiso-
merase II-mediated DNA cleavage throughout the genome,
coupled with the lack of specificity toward cancer cells, lim-
its the safe usage of these drugs. Among the most insidi-
ous of toxicities related with treatment with topoisomerase
II poisons is the development of secondary leukemias
(17,23,49,57). Indeed, as many as 3% of patients treated
with etoposide or doxorubicin develop AMLs with translo-
cations at chromosomal band 11q23 (58,59) or treated with
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
0–500Metoposide. Lanes 17–22 contain the unmodified parentalRARA
top strand hybridized to the 50-mer, 30-mer, or 20-mer PML-RARA OTI
bottom strand in the absence or presence of enzyme. Lanes 13 and 23 con-
tain a combination of reference (R) oligonucleotides 24, 23, 20 and 19 bases
in length. Gels are representative of at least three independent experiments.
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mitoxantrone develop APLs with t(15;17) translocations
(42,60).
One approach to providing anticancer agents with re-
duced toxicities is to develop drugs that specifically inhibit
the activity of driver oncoproteins. An example is imatinib,
which targets the TK domain of the bcr-abl fusion tyrosine
kinase that is generated by the chromosomal translocation
in chronic myelogenous leukemia (61). An alternative ap-
proach would be to target the chromosomal translocation
itself by specifically cleaving the DNA in the vicinity of the
translocation site. This could lead to disruption of the onco-
gene or could interfere with its transcription. If either oc-
curred, it ultimately could rob the cell of the oncoprotein
that drives malignant tumor growth.
Previous attempts to impart specificity to topoisomerase-
targeted drugs were based on the attachment of either
camptothecin (a topoisomerase I poison) (62) or etopo-
side derivatives (63) to the ends of triplex-forming oligonu-
cleotides. The attached camptothecin induced topoiso-
merase I-mediated DNA scission at sites that were consis-
tent with the location of the linked drug (62). However,
cleavage appeared to be constrained to pre-existing cleav-
age sites (62). In contrast, the attachment of etoposide to
the end of a triplex-forming oligonucleotide induced DNA
cleavage at locations that were approximately 10 base pairs
away from sites that could have come into physical contact
with the drug based on the length of the drug and linkers
employed (63). Thus, the basis for etoposide-induced DNA
cleavage that resulted from the triplex-forming oligonu-
cleotides could not be determined (63).
Although the present study also utilized drug-linked
oligonucleotides to enhance the specificity of etoposide-
induced DNA cleavage, we took the approach of design-
ing sequences that would form duplex (rather than triplex)
structures at the proposed sites of cleavage. To this end, a
series of oligonucleotides that contained a linked etoposide
core (OTIs) was synthesized using a copper-catalyzed click
chemistry scheme. OTIs were designed to take advantage of
the following: 1. Etoposide acts by a known mechanism in
which it enhances DNA cleavage mediated by type II topoi-
somerases (2,7,22). 2. The type II enzymes are validated tar-
gets for chemotherapeutic agents (2,15,16,22). 3. Levels of
type II topoisomerases are generally higher in malignant
cells, which generates higher levels of DNA strand breaks
in treated cells (64,65). 4. Cancer cells often have high
metabolic rates, which results in more replication and tran-
scription complexes that convert topoisomerase II-DNA
cleavage complexes into permanent double-strand breaks
(2,10,15).
Results indicate that the tethered etoposide core in OTIs
acts against type II topoisomerases in a manner similar to
that of the free drug, but with a specificity (at least for the
major sites of cleavage) that is tied to its site of linkage on
the oligonucleotide. Furthermore, the linked drug can in-
duce enzyme-mediated DNA cleavage at sites of action of
the free drug or at sites at which free drug does not act. This
finding suggests that it might be possible to develop OTIs
against a broad range of translocation-related sequences.
Results further suggest that OTIs can be designed to have
high activity against cancer-related breakpoints but display
limited activity against the parental genes.
It is notable that in some cases minor cleavage was ob-
served at positions that were not predicted from modeling
studies (Figures 1, 4 and Supplementary Figures S3 and S4).
Although the basis for cleavage at these minor sites is not
obvious, it is possible that they are induced by distortions
in the oligonucleotide caused by the presence of the OTI.
Alternatively, an OTI attached to the transport helix could
act in trans to induce cleavage within the gate helix (Figure
1A). However, this seems unlikely, as cleavage patterns for
these minor sites do not coincide with those observed in the
presence of free etoposide (compare Figures 3–8).
In order for OTIs to function in cells and block the ex-
pression of driver oncogenes, they would have to hybridize
to their target sequence. It is envisioned that this could po-
tentially take place when the two strands of the double helix
are separated during replication or transcription. In vitro ex-
periments suggest that single-stranded oligonucleotides as
short as 24-mers can invade the double helix and form a D-
loop (66). Alternatively, invasion can be greatly enhanced
by the presence of recombination proteins (67,68). Experi-
ments are currently underway to assess the ability of OTIs
to invade the double helix under a variety of conditions.
The development of oligonucleotide-based therapeutics
has been challenging (69). However, improved chemistry
and targeted delivery systems, together with the recent FDA
approval of new RNA therapeutics (69), hold promise for
the potential development of oligonucleotide-based agents.
Future studies will be directed toward determining the ef-
fects of the OTIs in normal and cancer cells.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
We are grateful to Rachel E. Ashley and Elizabeth G. Gib-
son for critical reading of the manuscript, Ben Andrews for
early discussions about chemistry, Steve Jackson for help
with chiral separations, Mark Edbrooke for support and
advice on oligonucleotide delivery, Neil McDonald for sup-
port in early stages of the project, and Andrew Leach for
support and advice.
FUNDING
National Institutes of Health (NIH) [GM033944 and
GM126363 to N.O.]; NIH [GM008554 to L.I.L.]. Funding
for open access charge: NIH grant GM126363.
Conflict of interest statement.None declared.
REFERENCES
1. Deweese,J.E., Osheroff,M.A. and Osheroff,N. (2008) DNA topology
and topoisomerases: teaching a “knotty” subject. Biochem. Mol. Biol.
Educ., 37, 2–10.
2. Deweese,J.E. and Osheroff,N. (2009) The DNA cleavage reaction of
topoisomerase II: wolf in sheep’s clothing. Nucleic Acids Res., 37,
738–748.
3. Nitiss,J.L. (2009) DNA topoisomerase II and its growing repertoire
of biological functions. Nat. Rev. Cancer, 9, 327–337.
4. Vos,S.M., Tretter,E.M., Schmidt,B.H. and Berger,J.M. (2011) All
tangled up: how cells direct, manage and exploit topoisomerase
function. Nat. Rev. Mol. Cell. Biol., 12, 827–841.
2232 Nucleic Acids Research, 2018, Vol. 46, No. 5
5. Chen,S.H., Chan,N.-L. and Hsieh,T.-S. (2013) New mechanistic and
functional insights into DNA topoisomerases. Ann. Rev. Biochem.,
82, 139–170.
6. Pommier,Y., Sun,Y., Huang,S.-y.N. and Nitiss,J.L. (2016) Roles of
eukaryotic topoisomerases in transcription, replication and genomic
stability. Nat. Rev. Mol. Cell Biol., 17, 703–721.
7. Osheroff,N. (1989) Effect of antineoplastic agents on the DNA
cleavage/religation reaction of eukaryotic topoisomerase II:
inhibition of DNA religation by etoposide. Biochemistry, 28,
6157–6160.
8. Bromberg,K.D., Burgin,A.B. and Osheroff,N. (2003) A two-drug
model for etoposide action against human topoisomerase II. J. Biol.
Chem., 278, 7406–7412.
9. Deweese,J.E. and Osheroff,N. (2010) The use of divalent metal ions
by type II topoisomerases.Metallomics, 2, 450–459.
10. Yu,X., Davenport,J.W., Urtishak,K.A., Carillo,M.L., Gosai,S.J.,
Kolaris,C.P., Byl,J.A.W., Rappaport,E.F., Osheroff,N., Gregory,B.D.
et al. (2017) Genome-wide TOP2A DNA cleavage is biased toward
translocated and highly transcribed loci. Genome Res., 27, 1238–1249.
11. Ju,B.G. and Rosenfeld,M.G. (2006) A breaking strategy for
topoisomerase II/PARP-1-dependent regulated transcription. Cell
Cycle, 5, 2557–2560.
12. Ju,B.G., Lunyak,V.V., Perissi,V., Garcia-Bassets,I., Rose,D.W.,
Glass,C.K. and Rosenfeld,M.G. (2006) A topoisomerase
II-mediated dsDNA break required for regulated transcription.
Science, 312, 1798–1802.
13. Yang,X., Li,W., Prescott,E.D., Burden,S.J. and Wang,J.C. (2000)
DNA topoisomerase II and neural development. Science, 287,
131–134.
14. Lyu,Y.L. and Wang,J.C. (2003) Aberrant lamination in the cerebral
cortex of mouse embryos lacking DNA topoisomerase II. Proc.
Natl. Acad. Sci. U.S.A., 100, 7123–7128.
15. Nitiss,J.L. (2009) Targeting DNA topoisomerase II in cancer
chemotherapy. Nat. Rev. Cancer, 9, 338–350.
16. Pommier,Y. (2013) Drugging topoisomerases: lessons and challenges.
ACS Chem. Biol., 8, 82–95.
17. Pendleton,M., Lindsey,R.H. Jr, Felix,C.A., Grimwade,D. and
Osheroff,N. (2014) Topoisomerase II and leukemia. Ann. N.Y. Acad.
Sci., 1310, 98–110.
18. Wu,C.C., Li,T.K., Farh,L., Lin,L.Y., Lin,T.S., Yu,Y.J., Yen,T.J.,
Chiang,C.W. and Chan,N.L. (2011) Structural basis of type II
topoisomerase inhibition by the anticancer drug etoposide. Science,
333, 459–462.
19. Woessner,R.D., Mattern,M.R., Mirabelli,C.K., Johnson,R.K. and
Drake,F.H. (1991) Proliferation- and cell cycle-dependent differences
in expression of the 170 kilodalton and 180 kilodalton forms of
topoisomerase II in NIH-3T3 cells. Cell Growth Differ., 2, 209–214.
20. Puigvert,J.C., Sanjiv,K. and Helleday,T. (2016) Targeting DNA
repair, DNA metabolism and replication stress as anti-cancer
strategies. FEBS J., 283, 232–245.
21. Murai,J. (2017) Targeting DNA repair and replication stress in the
treatment of ovarian cancer. Int. J. Clin. Oncol., 22, 619–628.
22. Baldwin,E.L. and Osheroff,N. (2005) Etoposide, topoisomerase II
and cancer. Curr. Med. Chem. Anticancer Agents, 5, 363–372.
23. Felix,C.A., Kolaris,C.P. and Osheroff,N. (2006) Topoisomerase II and
the etiology of chromosomal translocations. DNA Repair (Amst.), 5,
1093–1108.
24. Joannides,M., Mays,A.N., Mistry,A.R., Hasan,S.K., Reiter,A.,
Wiemels,J.L., Felix,C.A., Coco,F.L., Osheroff,N., Solomon,E. et al.
(2011) Molecular pathogenesis of secondary acute promyelocytic
leukemia.Mediterr. J. Hematol. Infect. Dis., 3, e2011045.
25. Cowell,I.G. and Austin,C.A. (2012) Mechanism of generation of
therapy related leukemia in response to anti-topoisomerase II agents.
Int. J. Environ. Res. Public Health, 9, 2075–2091.
26. Cowell,I.G., Sondka,Z., Smith,K., Lee,K.C., Manville,C.M.,
Sidorczuk-Lesthuruge,M., Rance,H.A., Padget,K., Jackson,G.H.,
Adachi,N. et al. (2012) Model for MLL translocations in
therapy-related leukemia involving topoisomerase II-mediated
DNA strand breaks and gene proximity. Proc. Natl. Acad. Sci.
U.S.A., 109, 8989–8994.
27. Rowley,J.D. (1973) A new consistent chromosomal abnormality in
chronic myelogenous leukaemia identified by quinacrine fluorescence
and Giemsa staining. Nature, 243, 290–293.
28. Barreca,A., Lasorsa,E., Riera,L., Machiorlatti,R., Piva,R.,
Ponzoni,M., Kwee,I., Bertoni,F., Piccaluga,P.P., Pileri,S.A. et al.
(2011) Anaplastic lymphoma kinase in human cancer. J. Mol.
Endocrinol., 47, R11–R23.
29. Stenman,G. (2013) Fusion oncogenes in salivary gland tumors:
molecular and clinical consequences. Head Neck Pathol., 7(Suppl. 1),
S12–S19.
30. Hasan,S.K., Mays,A.N., Ottone,T., Ledda,A., La Nasa,G.,
Cattaneo,C., Borlenghi,E., Melillo,L., Montefusco,E., Cervera,J.
et al. (2008) Molecular analysis of t(15;17) genomic breakpoints in
secondary acute promyelocytic leukemia arising after treatment of
multiple sclerosis. Blood, 112, 3383–3390.
31. Emsley,P. (2017) Tools for ligand validation in Coot. Acta.
Crystallogr. D. Struct. Biol., 73, 203–210.
32. Chemical Computing Group ULC (2017) 1010 Sherbooke St. West,
Suite #910, Montreal, QC, Canada, H3A,2R7, Vol. 2013.08.
33. Wang,Y.-R., Chen,S.-F., Wu,C.-C., Liao,Y.-W., Lin,T.-S., Liu,K.-T.,
Chen,Y.-S., Li,T.-K., Chien,T.-C. and Chan,N.-L. (2017) Producing
irreversible topoisomerase II-mediated DNA breaks by site-specific
Pt(II)-methionine coordination chemistry. Nucleic Acids Res., 45,
10861–10871.
34. Chan,P.F., Srikannathasan,V., Huang,J., Cui,H., Fosberry,A.P.,
Gu,M., Hann,M.M., Hibbs,M., Homes,P., Ingraham,K. et al. (2015)
Structural basis of DNA gyrase inhibition by antibacterial QPT-1,
anticancer drug etoposide and moxifloxacin.Nat. Commun., 6, 10048.
35. Schmidt,B.H., Burgin,A.B., Deweese,J.E., Osheroff,N. and
Berger,J.M. (2010) A novel and unified two-metal mechanism for
DNA cleavage by type II and IA topoisomerases. Nature, 465,
641–644.
36. Worland,S.T. and Wang,J.C. (1989) Inducible overexpression,
purification, and active site mapping of DNA topoisomerase II from
the yeast Saccharomyces cerevisiae. J. Biol. Chem., 264, 4412–4416.
37. Wasserman,R.A., Austin,C.A., Fisher,L.M. and Wang,J.C. (1993)
Use of yeast in the study of anticancer drugs targeting DNA
topoisomerases: expression of a functional recombinant human DNA
topoisomerase II in yeast. Cancer Res., 53, 3591–3596.
38. Elsea,S.H., Hsiung,Y., Nitiss,J.L. and Osheroff,N. (1995) A yeast type
II topoisomerase selected for resistance to quinolones. Mutation of
histidine 1012 to tyrosine confers resistance to nonintercalative drugs
but hypersensitivity to ellipticine. J. Biol. Chem., 270, 1913–1920.
39. Kingma,P.S., Greider,C.A. and Osheroff,N. (1997) Spontaneous
DNA lesions poison human topoisomerase II and stimulate
cleavage proximal to leukemic 11q23 chromosomal breakpoints.
Biochemistry, 36, 5934–5939.
40. Byl,J.A., Cline,S.D., Utsugi,T., Kobunai,T., Yamada,Y. and
Osheroff,N. (2001) DNA topoisomerase II as the target for the
anticancer drug TOP-53: mechanistic basis for drug action.
Biochemistry, 40, 712–718.
41. Liu,Q. and Wang,J.C. (1998) Identification of active site residues in
the “GyrA” half of yeast DNA topoisomerase II. J. Biol. Chem., 273,
20252–20260.
42. Mistry,A.R., Felix,C.A., Whitmarsh,R.J., Mason,A., Reiter,A.,
Cassinat,B., Parry,A., Walz,C., Wiemels,J.L., Segal,M.R. et al. (2005)
DNA topoisomerase II in therapy-related acute promyelocytic
leukemia. N. Engl. J. Med., 352, 1529–1538.
43. Deweese,J.E., Burgin,A.B. and Osheroff,N. (2008) Using 3′-bridging
phosphorothiolates to isolate the forward DNA cleavage reaction of
human topoisomerase II. Biochemistry, 47, 4129–4140.
44. Byl,J.A., Fortune,J.M., Burden,D.A., Nitiss,J.L., Utsugi,T.,
Yamada,Y. and Osheroff,N. (1999) DNA topoisomerases as targets
for the anticancer drug TAS-103: Primary cellular target and DNA
cleavage enhancement. Biochemistry, 38, 15573–15579.
45. Bromberg,K.D., Velez-Cruz,R., Burgin,A.B. and Osheroff,N. (2004)
DNA ligation catalyzed by human topoisomerase II. Biochemistry,
43, 13416–13423.
46. Bandele,O.J. and Osheroff,N. (2008) The efficacy of topoisomerase
II-targeted anticancer agents reflects the persistence of drug-induced
cleavage complexes in cells. Biochemistry, 47, 11900–11908.
47. Wilstermann,A.M., Bender,R.P., Godfrey,M., Choi,S., Anklin,C.,
Berkowitz,D.B., Osheroff,N. and Graves,D.E. (2007) Topoisomerase
II - drug interaction domains: Identification of substituents on
etoposide that interact with the enzyme. Biochemistry, 46, 8217–8225.
48. Bender,R.P., Jablonksy,M.J., Shadid,M., Romaine,I., Dunlap,N.,
Anklin,C., Graves,D.E. and Osheroff,N. (2008) Substituents on
Nucleic Acids Research, 2018, Vol. 46, No. 5 2233
etoposide that interact with human topoisomerase II in the binary
enzyme-drug complex: Contributions to etoposide binding and
activity. Biochemistry, 47, 4501–4509.
49. Joannides,M. and Grimwade,D. (2010) Molecular biology of
therapy-related leukaemias. Clin. Transl. Oncol., 12, 8–14.
50. Kingma,P.S. and Osheroff,N. (1998) The response of eukaryotic
topoisomerases to DNA damage. Biochim. Biophys. Acta, 1400,
223–232.
51. Sabourin,M. and Osheroff,N. (2000) Sensitivity of human type II
topoisomerases to DNA damage: stimulation of enzyme-mediated
DNA cleavage by abasic, oxidized and alkylated lesions. Nucleic
Acids Res., 28, 1947–1954.
52. Elsea,S.H., Hsiung,Y., Nitiss,J.L. and Osheroff,N. (1995) A yeast type
II topoisomerase selected for resistance to quinolones. Mutation of
histidine 1012 to tyrosine confers resistance to nonintercalative drugs
but hypersensitivity to ellipticine. J. Biol. Chem., 270, 1913–1920.
53. Matsumoto,Y., Takano,H., Kunishio,K., Nagao,S. and Fojo,T.
(2001) Incidence of mutation and deletion in topoisomerase II
mRNA of etoposide and mAMSA-resistant cell lines. Jpn. J. Cancer
Res., 92, 1133–1137.
54. Kanagasabai,R., Serdar,L., Karmahapatra,S., Kientz,C.A., Ellis,J.,
Ritke,M.K., Elton,T.S. and Yalowich,J.C. (2017) Alternative RNA
processing of topoisomerase II in etoposide-resistant human
leukemia K562 cells: intron retention results in a novel C-terminal
truncated 90-kDa isoform. J. Pharmacol. Exp. Ther., 360, 152–163.
55. Kingma,P.S., Burden,D.A. and Osheroff,N. (1999) Binding of
etoposide to topoisomerase II in the absence of DNA: decreased
affinity as a mechanism of drug resistance. Biochemistry, 38,
3457–3461.
56. Bender,R.P. and Osheroff,N. (2008) In: Dai,W (ed). Checkpoint
Responses in Cancer Therapy. 1st edn. Humana Press, Totowa, pp.
57–91.
57. Mays,A.N., Osheroff,N., Xiao,Y., Wiemels,J.L., Felix,C.A., Byl,J.A.,
Saravanamuttu,K., Peniket,A., Corser,R., Chang,C. et al. (2010)
Evidence for direct involvement of epirubicin in the formation of
chromosomal translocations in t(15;17) therapy-related acute
promyelocytic leukemia. Blood, 115, 326–330.
58. Ratain,M.J., Kaminer,L.S., Bitran,J.D., Larson,R.A., Le Beau,M.M.,
Skosey,C., Purl,S., Hoffman,P.C., Wade,J., Vardiman,J.W. et al.
(1987) Acute nonlymphocytic leukemia following etoposide and
cisplatin combination chemotherapy for advanced non-small-cell
carcinoma of the lung. Blood, 70, 1412–1417.
59. DeVore,R., Whitlock,J., Hainsworth,J.D. and Johnson,D.H. (1989)
Therapy-related acute nonlymphocytic leukemia with monocytic
features and rearrangement of chromosome 11q. Ann. Intern. Med.,
110, 740–742.
60. Ramkumar,B., Chadha,M.K., Barcos,M., Sait,S.N., Heyman,M.R.
and Baer,M.R. (2008) Acute promyelocytic leukemia after
mitoxantrone therapy for multiple sclerosis. Cancer Genet.
Cytogenet., 182, 126–129.
61. Druker,B.J., Tamura,S., Buchdunger,E., Ohno,S., Segal,G.M.,
Fanning,S., Zimmermann,J. and Lydon,N.B. (1996) Effects of a
selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl
positive cells. Nat. Med., 2, 561–566.
62. Arimondo,P.B., Thomas,C.J., Oussedik,K., Baldeyrou,B., Mahieu,C.,
Halby,L., Guianvarc’h,D., Lansiaux,A., Hecht,S.M., Bailly,C. et al.
(2006) Exploring the cellular activity of
camptothecin-triple-helix-forming oligonucleotide conjugates.Mol.
Cell Biol., 26, 324–333.
63. Duca,M., Guianvarc’h,D., Oussedik,K., Halby,L., Garbesi,A.,
Dauzonne,D., Monneret,C., Osheroff,N., Giovannangeli,C. and
Arimondo,P.B. (2006) Molecular basis of the targeting of
topoisomerase II-mediated DNA cleavage by VP16 derivatives
conjugated to triplex-forming oligonucleotides. Nucleic Acids Res.,
34, 1900–1911.
64. Davies,S.M., Robson,C.N., Davies,S.L. and Hickson,I.D. (1988)
Nuclear topoisomerase II levels correlate with the sensitivity of
mammalian cells to intercalating agents and epipodophyllotoxins. J.
Biol. Chem., 263, 17724–17729.
65. Coutts,J., Plumb,J.A., Brown,R. and Keith,W.N. (1993) Expression of
topoisomerase II and  in an adenocarcinoma cell line carrying
amplified topoisomerase II and retinoic acid receptor alpha genes.
Br. J. Cancer, 68, 793–800.
66. Necasova,I., Janouskova,E., Klumpler,T. and Hofr,C. (2017) Basic
domain of telomere guardian TRF2 reduces D-loop unwinding
whereas Rap1 restores it. Nucleic Acids Res., 45, 12170–12180.
67. Li,X., Stith,C.M., Burgers,P.M. and Heyer,W.D. (2009) PCNA is
required for initiation of recombination-associated DNA synthesis by
DNA polymerase delta.Mol. Cell, 36, 704–713.
68. Bower,B.D. and Griffith,J.D. (2014) TRF1 and TRF2 differentially
modulate Rad51-mediated telomeric and nontelomeric displacement
loop formation in vitro. Biochemistry, 53, 5485–5495.
69. Kaczmarek,J.C., Kowalski,P.S. and Anderson,D.G. (2017) Advances
in the delivery of RNA therapeutics: from concept to clinical reality.
Genome Med., 9, 60–75.
